{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:21:13Z","timestamp":1782944473527,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11096-016-0420-4","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T03:41:15Z","timestamp":1484624475000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit"],"prefix":"10.1007","volume":"39","author":[{"given":"P.","family":"Joret-Descout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bellaiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Prot-Labarthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"420_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","volume":"15","author":"RM Ward","year":"2013","unstructured":"Ward RM, Kearns GL. Proton pump inhibitors in pediatrics. Paediatr Drugs. 2013;15:119\u201331.","journal-title":"Paediatr Drugs"},{"key":"420_CR2","first-page":"153","volume":"59","author":"CH Smith","year":"2013","unstructured":"Smith CH, Israel DM, Schreiber R, Goldman RD. Proton pump inhibitors for irritable infants. Can Fam Physician. 2013;59:153\u20136.","journal-title":"Can Fam Physician"},{"key":"420_CR3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/phar.1299","volume":"33","author":"JA Tjon","year":"2013","unstructured":"Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy. 2013;33:956\u201371.","journal-title":"Pharmacotherapy"},{"key":"420_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00228-008-0560-0","volume":"65","author":"G Tafuri","year":"2009","unstructured":"Tafuri G, Trotta F, Leufkens HGM, Martini N, Sagliocca L, Traversa G. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol. 2009;65:209\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"56","key":"420_CR5","first-page":"347","volume":"15","author":"ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis","year":"1999","unstructured":"ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;15(56):347\u201379.","journal-title":"Am J Health Syst Pharm"},{"key":"420_CR6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/aas.12099","volume":"57","author":"M Krag","year":"2013","unstructured":"Krag M, Perner A, Wetterslev J, M\u00f8ller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand. 2013;57:835\u201347.","journal-title":"Acta Anaesthesiol Scand"},{"key":"420_CR7","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1572-0241.2000.03189.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol. 2000;95:2801\u20136.","journal-title":"Am J Gastroenterol"},{"key":"420_CR8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/cc1071","volume":"5","author":"DJ Cook","year":"2001","unstructured":"Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5:368\u201375.","journal-title":"Crit Care"},{"key":"420_CR9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/CCM.0b013e3182758734","volume":"41","author":"W Alhazzani","year":"2013","unstructured":"Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693\u2013705.","journal-title":"Crit Care Med"},{"key":"420_CR10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","volume":"183","author":"CS Eom","year":"2011","unstructured":"Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310\u20139.","journal-title":"CMAJ"},{"key":"420_CR11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"MD Howell","year":"2010","unstructured":"Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784\u201390.","journal-title":"Arch Intern Med"},{"key":"420_CR12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamainternmed.2013.14673","volume":"174","author":"R MacLaren","year":"2014","unstructured":"MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174:564\u201374.","journal-title":"JAMA Intern Med"},{"key":"420_CR13","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/CCM.0b013e3181f17adf","volume":"38","author":"PE Marik","year":"2010","unstructured":"Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38:2222\u20138.","journal-title":"Crit Care Med"},{"key":"420_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1756283X12437358","volume":"5","author":"JJ Heidelbaugh","year":"2012","unstructured":"Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219\u201332.","journal-title":"Ther Adv Gastroenterol"},{"key":"420_CR15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18553\/jmcp.2010.16.2.122","volume":"16","author":"L Thomas","year":"2010","unstructured":"Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122\u20139.","journal-title":"J Manag Care Pharm"},{"key":"420_CR16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1542\/peds.2013-0421","volume":"131","author":"JR Lightdale","year":"2013","unstructured":"Lightdale JR, Gremse DA. Section on gastroenterology, hepatology and nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131:1684\u201395.","journal-title":"Pediatrics"},{"key":"420_CR17","unstructured":"French National Agency for the Safety of Medicines and Health Products. Good practice guidelines for the use of gastric anti-secretory agents in children issued in June 2008. http:\/\/www.omedit-hautenormandie.fr\/Files\/110_recommandations_antisecretoire_enfants.pdf . Accessed 08 Dec 2016."},{"key":"420_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MPG.0b013e318272af3b","volume":"55","author":"H Winter","year":"2012","unstructured":"Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1\u201311 months. J Pediatr Gastroenterol Nutr. 2012;55:14\u201320.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"420_CR19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/MPG.0b013e31819de871","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498\u2013547.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"420_CR20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcrc.2009.05.014","volume":"25","author":"CP Farrell","year":"2010","unstructured":"Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25:214\u201320.","journal-title":"J Crit Care"},{"key":"420_CR21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/00003246-198811000-00006","volume":"16","author":"MM Pollack","year":"1988","unstructured":"Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16:1110\u20136.","journal-title":"Crit Care Med"},{"key":"420_CR22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00134-002-1601-2","volume":"29","author":"A Slater","year":"2003","unstructured":"Slater A, Shann F, Pearson G. Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003;29:278\u201385.","journal-title":"Intensive Care Med"},{"key":"420_CR23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(06)68371-2","volume":"367","author":"S Leteurtre","year":"2006","unstructured":"Leteurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F. Paediatric logistic organ dysfunction (PELOD) score. Lancet. 2006;367:897 (author reply 900\u20132).","journal-title":"Lancet"},{"key":"420_CR24","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00431-013-2111-7","volume":"172","author":"C Carnovale","year":"2013","unstructured":"Carnovale C, Conti V, Perrone V, Antoniazzi S, Pozzi M, Merlino L, et al. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172:1679\u201385.","journal-title":"Eur J Pediatr"},{"key":"420_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00508-014-0637-y","volume":"127","author":"K Lenz","year":"2015","unstructured":"Lenz K, Buder R, Firlinger F, Lohr G, Voglmayr M. Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress. Wien Klin Wochenschr. 2015;127:51\u20136.","journal-title":"Wien Klin Wochenschr"},{"key":"420_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042533313497183","volume":"4","author":"M Haroon","year":"2013","unstructured":"Haroon M, Yasin F, Gardezi S, Adeeb F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4:1\u20136.","journal-title":"JRSM Short Rep."},{"key":"420_CR27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jcrc.2014.06.025","volume":"29","author":"JF Barletta","year":"2014","unstructured":"Barletta JF, Kanji S, MacLaren R, Lat I, Erstad BL. American-Canadian consortium for Intensive care Drug utilization (ACID) Investigators. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care. 2014;29:955\u201360.","journal-title":"J Crit Care"},{"key":"420_CR28","first-page":"283","volume":"14","author":"A Gautam","year":"2012","unstructured":"Gautam A, Ganu SS, Tegg OJ, Andresen DN, Wilkins BH, Schell DN. Ventilator-associated pneumonia in a tertiary paediatric intensive care unit: a 1-year prospective observational study. Crit Care Resusc. 2012;14:283\u20139.","journal-title":"Crit Care Resusc"},{"key":"420_CR29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4140\/TCP.n.2013.786","volume":"28","author":"R Atkins","year":"2013","unstructured":"Atkins R, Smith L. Impact of pharmacy intervention on the use of proton-pump inhibitors in the hospital setting. Consult Pharm. 2013;28:786\u201392.","journal-title":"Consult Pharm"},{"key":"420_CR30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/SMJ.0b013e31828db01f","volume":"106","author":"F Leri","year":"2013","unstructured":"Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA Jr. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106:270\u20133.","journal-title":"South Med J"},{"key":"420_CR31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4321\/S1130-01082014000200002","volume":"106","author":"JE Machado-Alba","year":"2014","unstructured":"Machado-Alba JE, Castrill\u00f3n-Spitia JD, Londo\u00f1o-Builes MJ, Fern\u00e1ndez-Cardona A, Campo-Betancourth CF, Ochoa-Orozco SA, et al. An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia. Rev Esp Enferm Dig. 2014;106:77\u201385.","journal-title":"Rev Esp Enferm Dig"},{"key":"420_CR32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/CCM.0000000000000032","volume":"42","author":"R MacLaren","year":"2014","unstructured":"MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med. 2014;42:809\u201315.","journal-title":"Crit Care Med"},{"key":"420_CR33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40273-013-0119-5","volume":"32","author":"JF Barletta","year":"2014","unstructured":"Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics. 2014;32:5\u201313.","journal-title":"Pharmacoeconomics"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-016-0420-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T21:42:30Z","timestamp":1658439750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-016-0420-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1007\/s11096-016-0420-4","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]}}}